Luput Cristian

SEC source: 0001878313-26-000098 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,536

Underlying: Common Stock · 33,536 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000071 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,610

Underlying: Common Stock · 27,610 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000033 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,556

Underlying: Common Stock · 28,556 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000014 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,206

Underlying: Common Stock · 25,206 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000054 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,628

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1147 to $1.1192, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-25-000054 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,483

SEC source: 0001878313-25-000050 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,483

SEC source: 0001878313-25-000033 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,434

Underlying: Common Stock · 21,434 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-018651 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,350

Underlying: Common Stock · 21,350 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-011811 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,042

Underlying: Common Stock · 21,042 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-25-000411 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,225

Underlying: Common Stock · 10,225 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-026386 · form4.xml · derivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,133

Underlying: Common Stock · 22,133 shares

Expires 2030-05-01

F2 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on November 1, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-026386 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 389,483

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on November 1, 2024.

SEC source: 0001127602-24-024944 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,232

Underlying: Common Stock · 7,232 shares

Expires 2034-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of thate date.

SEC source: 0001127602-24-019848 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,728

Underlying: Common Stock · 5,728 shares

Expires 2034-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-011882 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,193

Underlying: Common Stock · 9,193 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-010323 · form4.xml · derivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,282

Underlying: Common Stock · 69,282 shares

Expires 2029-09-14

F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-010323 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 367,350

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024.

SEC source: 0001127602-24-000652 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,418

Underlying: Common Stock · 15,418 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025157 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,378

Underlying: Common Stock · 8,378 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-019770 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,910

Underlying: Common Stock · 8,910 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-015796 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 298,068

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of Mr. Luput that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.505 to $2.74, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-013028 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 295,068

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.60 to $3.85, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-012944 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 293,492

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of Mr. Luput that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.55 to $3.65, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-012944 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292,690

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of Mr. Luput that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.57 to $3.70, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-012011 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,675

Underlying: Common Stock · 5,675 shares

Expires 2033-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-009989 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,068

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.90 to $4.145, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-009989 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,068

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.985 to $4.00, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-009696 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,686

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.94 to $4.00, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-009696 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,572

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.21 to $4.24, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-009395 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,945

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-009395 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,257

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.23 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-006043 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,730

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchanage Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.23 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-006043 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,654

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchanage Act of 1934, as amended.

SEC source: 0001127602-23-005438 · form4.xml · nonDerivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,596

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of Mr. Luput that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-23-005438 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,586

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of Mr. Luput that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-23-001508 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,572

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Luput that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchanage Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.77 to $4.00, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-000645 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,045

Underlying: Common Stock · 3,045 shares

Expires 2032-12-30

F1 · derivative.exercise_date: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0000899243-22-027452 · doc4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,068

F1 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022.